Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355024 | 0.96 | — | — | |
| SCHEMBL17355036 | 0.95 | — | — | |
| SCHEMBL17355020 | 0.92 | — | — | |
| SCHEMBL15062104 | 0.92 | CYP1A2 (0.38) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL17354982 | 0.89 | CYP1A2 (0.32) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL17355025 | 0.88 | CYP1A2 (0.31) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL17354981 | 0.88 | CYP1A2 (0.31) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL17355017 | 0.87 | — | — | |
| SCHEMBL17354979 | 0.86 | CYP1A2 (0.30) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL17355013 | 0.85 | GBA1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030350-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-02-01 | — | — | US | disclosed |
| US-20170044438-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044438-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| EP-2957618-A1 | LIQUID CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2015-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044438-A1 | LIQUID-CRYSTALLINE MEDIUM | VIM, COL2A1, COL1A1 | CYP1A2 3394/4885LMNA 40/4885MAPK1 1806/4885 |
| US-20180030350-A1 | LIQUID-CRYSTALLINE MEDIUM | VIM, COL2A1, COL1A1 | CYP1A2 3394/4885LMNA 40/4885MAPK1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.